Literature DB >> 10897069

Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity.

Y Gomi1, T Imagawa, M Takahashi, K Yamanishi.   

Abstract

When the nucleotide sequences of the Oka vaccine and its parental varicella-zoster virus (VZV) were compared in 6 open reading frames (ORFs), glycoprotein C (gC) and 5 transactivator genes, mutations were detected only in the immediate-early gene 62. The vaccine virus contained a mixture of different sequences that had variations at 15 nucleotide positions, but only one sequence was found for the Oka parental virus gene 62. The Oka vaccine virus gene 62 could be distinguished from the parental virus gene using a simplified restriction-enzyme fragment length polymorphism analysis, using NaeI and BssHII. This analysis was based on the sequence data obtained in this study. Studies of the regulatory activities of the ORF62 gene product (IE62) in a transient transfection assay indicated that IE62 of the parental virus had a stronger transactivational activity than that of the vaccine virus in activating immediate-early, early, and late gene promoters. These data suggest that IE62 might play an important role in the attenuation of VZV. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897069     DOI: 10.1002/1096-9071(200008)61:4<497::aid-jmv13>3.0.co;2-2

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  24 in total

Review 1.  25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview.

Authors:  M Takahashi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

2.  Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus.

Authors:  Yasuyuki Gomi; Hiroki Sunamachi; Yasuko Mori; Kazuhiro Nagaike; Michiaki Takahashi; Koichi Yamanishi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Stable and consistent genetic profile of Oka varicella vaccine virus is not linked with appearance of infrequent breakthrough cases postvaccination.

Authors:  Ventzislav Vassilev
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

5.  Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.

Authors:  Sonja Thiele; Aljona Borschewski; Judit Küchler; Marc Bieberbach; Sebastian Voigt; Bernhard Ehlers
Journal:  Clin Vaccine Immunol       Date:  2011-05-11

6.  Population diversity in batches of the varicella Oka vaccine.

Authors:  R K Kanda; M L Quinlivan; A A Gershon; R A Nichols; J Breuer
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

7.  Detection and genotyping of varicella-zoster virus by TaqMan allelic discrimination real-time PCR.

Authors:  Paul A Campsall; Nicholas H C Au; Julie S Prendiville; David P Speert; Rusung Tan; Eva E Thomas
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  Varicella-zoster virus infection of human neural cells in vivo.

Authors:  Armin Baiker; Klaus Fabel; Antonio Cozzio; Leigh Zerboni; Konstanze Fabel; Marvin Sommer; Nobuko Uchida; Dongping He; Irving Weissman; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

9.  Complete DNA sequences of two oka strain varicella-zoster virus genomes.

Authors:  Sueli L Tillieux; Wendy S Halsey; Elizabeth S Thomas; John J Voycik; Ganesh M Sathe; Ventzislav Vassilev
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: evolution of genotypes with an accelerated cell spread phenotype.

Authors:  Charles Grose; Shaun Tyler; Geoff Peters; Joanne Hiebert; Gwen M Stephens; William T Ruyechan; Wallen Jackson; Johnathan Storlie; Graham A Tipples
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.